Flush With CF Success, Vertex Prepares Next-Gen Pipeline For Busy 2023

Sickle Cell Therapy Could Be Approved Next Year

 
• By Andrew McConaghie
  
Vertex Mobile
Vertex shares are up 35% so far this year, making it one of the sector's top mid-sized performers. • Source: Shutterstock
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Earnings

More from Business